JNJ 56136379

Drug Profile

JNJ 56136379

Alternative Names: JNJ-379; JNJ-56136379

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Sciences Ireland UC
  • Class Antivirals
  • Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 05 Dec 2017 Janssen Sciences Ireland UC plans a phase II trial for Hepatitis B (Monotherapy, Combination therapy, In adults, In the elderly) in Belgium, Hong Kong, Poland, Taiwan, USA and United Kingdom (NCT03361956)
  • 09 Sep 2017 Pharmacodynamics data from a preclinical trial in Hepatitis B presented at the The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 23 Aug 2017 Janssen completes a phase I trial in Healthy volunteers in Belgium (NCT03111511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top